Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal
hematopoietic disorders. Metaphase cytogenetics has been the gold standard for genetic …

The diagnosis of myelodysplastic syndromes (MDS) has been based on clinical
presentations, laboratory and morphological findings, and molecular and cytogenetic …

Implications of molecular genetic diversity in myelodysplast... : Current Opinion in
Hematology Implications of molecular genetic diversity in myelodysplastic syndromes …

Whole exome next generation sequencing systematically applied as a discovery tool in
myelodysplastic syndromes (MDS) has led to the identification of a large number of novel …

Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic neoplasms that are
driven by somatically acquired genetic mutations and epigenetic alterations. Accurate risk …

Myelodysplastic syndromes are a collection of clonal hematopoietic disorders with a wide
range of clinical manifestations and eventual outcomes. Accurate prediction of a patient's …

To develop a genetic risk model for primary myelodysplastic syndromes (MDS), we queried
the prognostic significance of next‐generation sequencing (NGS)‐derived mutations, in the …

The introduction into routine hematology-oncology clinical practice of molecular genetic
testing assays based on next-generation sequencing platforms is prompting reassessment …

The myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic
stem cell disorders characterized by ineffective hematopoiesis. Clinically, patients present …

How to best use the results of molecular mutation testing to inform clinical decision making
in MDS is still a work in progress. Important steps in this direction include standardization in …